Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies

Protein kinases are a primary focus in targeted therapy development for cancer, owing to their role as regulators in nearly all areas of cell life. Kinase inhibitors are one of the fastest growing drug classes in oncology, but resistance acquisition to kinase-targeting monotherapies is inevitable du...

Descripción completa

Detalles Bibliográficos
Autores principales: Joisa, Chinmaya U., Chen, Kevin A., Beville, Samantha, Stuhlmiller, Timothy, Berginski, Matthew E., Okumu, Denis, Golitz, Brian T., Johnson, Gary L., Gomez, Shawn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418192/
https://www.ncbi.nlm.nih.gov/pubmed/37577663
http://dx.doi.org/10.1101/2023.08.01.551346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418192/
https://www.ncbi.nlm.nih.gov/pubmed/37577663
http://dx.doi.org/10.1101/2023.08.01.551346

Ejemplares similares